March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
A New in vivo Model for Testing Treatments for Liver Metastases of Uveal Melanoma: Model Construction and Use for Testing NFkB Inhibition
Author Affiliations & Notes
  • Shahar Frenkel
    Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • Jacob Pe'er
    Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • Footnotes
    Commercial Relationships  Shahar Frenkel, None; Jacob Pe'er, None
  • Footnotes
    Support  The Dorrie H. Raskin fund for cancer oriented translational research.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3422. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shahar Frenkel, Jacob Pe'er; A New in vivo Model for Testing Treatments for Liver Metastases of Uveal Melanoma: Model Construction and Use for Testing NFkB Inhibition. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3422.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To describe a new animal model for in vivo testingof treatments for liver metastases of uveal melanoma, and its use for testing an NFkB inhibitor.

Methods: : A metastatic uveal melanoma cell line (C918) was transfected with the luciferase gene in a stable transfection. The new C918-Luc cell line was trypsinized, washed in 1xPBS and injected directly into the livers of C57Bl mice (for the model construction) or SCID mice (for testing the NFkB inhibitor) through a small (1cm) abdominal wall incision via a 0.5cc insulin syringe (29 gauge needle) in a non-reflux technique. Cells were allowed to settle for 1 week before administration of the BMS-345541 NFkB inhibitor. Intra-hepatic cells were visualized with an IVIS bioluminescence camera (Caliper Life Sciences, Hopkinton, MA USA) 10 minutes after injecting the mice with luciferin (IP 300mg/0.3cc). BMS-345541 (5mg/kg) was administered by oral gavage 3 times a week for 3 weeks, followed by euthanasia and harvesting of the livers for histopathologic evaluation. Bioluminescence was measured twice a week. The research reported here was conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Results: : Bioluminescence was detectable in the liver immediately post op, increased over a period of one week in C57Bl mice and then decreased and disappeared over another week. In SCID mice, bioluminescence started decreasing after administration of the inhibitor. Experiments are not finished yet. Final results of the in vivo effect of NFkB inhibition will be presented at the meeting.

Conclusions: : Combining the direct injection model with bioluminescence provides a way to follow the effect of anti-metastatic treatments in vivo. Inhibition of NFkB shows potential as a new treatment for metastatic uveal melanoma.

Keywords: melanoma • oncology • uvea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.